{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:39:36Z","timestamp":1784234376610,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560532"],"award-info":[{"award-number":["82560532"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232BAB206111"],"award-info":[{"award-number":["20232BAB206111"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) frequently acquires chemoresistance, leading to poor clinical outcomes. Phospholipid scramblase 1 (PLSCR1) has been implicated in breast cancer progression, yet its precise role and underlying mechanisms in TNBC chemoresistance remain elusive. Here, we demonstrate that PLSCR1 is significantly upregulated in chemoresistant TNBC cell lines and patient samples. Mechanistically, PLSCR1 interacts with EGFR, promoting its phosphorylation and subsequent activation of the MAPK signaling pathway, which in turn upregulates the efflux pumps P-gp and MRP1. Concurrently, PLSCR1 mRNA undergoes METTL3-mediated m6A modification, which is recognized by the m6A reader IGF2BP3, leading to enhanced mRNA stability and translational efficiency. Functional studies revealed that PLSCR1 knockdown resensitizes resistant cells to epirubicin, whereas its overexpression exacerbates resistance both in vitro and in vivo. Clinically, elevated PLSCR1 expression correlates with reduced sensitivity to neoadjuvant chemotherapy and poorer prognosis in TNBC patients. Notably, Mogroside IV-A, a specific PLSCR1 inhibitor, effectively overcomes chemoresistance by disrupting PLSCR1-mediated EGFR activation. Collectively, our findings establish PLSCR1 as a critical node integrating the METTL3\/IGF2BP3 epigenetic axis with EGFR-MAPK signaling to drive TNBC chemoresistance, and highlight PLSCR1 as a promising therapeutic target for combating drug resistance in TNBC.<\/jats:p>","DOI":"10.1038\/s41419-026-08845-4","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:03:55Z","timestamp":1778857435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PLSCR1 drives chemoresistance in TNBC via METTL3\/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation"],"prefix":"10.1038","volume":"17","author":[{"given":"Yao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueliang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-5070","authenticated-orcid":false,"given":"Yangyang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-7036","authenticated-orcid":false,"given":"Panpan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"8845_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"8845_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16:100.","journal-title":"J Hematol Oncol"},{"key":"8845_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00197-2","volume":"6","author":"A Marra","year":"2020","unstructured":"Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ breast cancer. 2020;6:54.","journal-title":"NPJ breast cancer"},{"key":"8845_CR4","doi-asserted-by":"crossref","unstructured":"Mason S, Beith J, Willson ML, Egger SJ, Dear RF, Goodwin A. Platinum-based chemotherapy for early triple-negative breast cancer. Cochrane Database Syst Rev. 2023;9:CD014805.","DOI":"10.1002\/14651858.CD014805.pub2"},{"key":"8845_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111879","volume":"389","author":"K Shi","year":"2020","unstructured":"Shi K, An J, Qian K, Zhao X, Li F, Ma X, et al. p53 controls the switch between autophagy and apoptosis through regulation of PLSCR1 in sodium selenite-treated leukemia cells. Exp cell Res. 2020;389:111879.","journal-title":"Exp cell Res"},{"key":"8845_CR6","doi-asserted-by":"publisher","first-page":"35062","DOI":"10.1074\/jbc.M504821200","volume":"280","author":"Q Zhou","year":"2005","unstructured":"Zhou Q, Ben-Efraim I, Bigcas JL, Junqueira D, Wiedmer T, Sims PJ. Phospholipid scramblase 1 binds to the promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene to enhance its expression. J Biol Chem. 2005;280:35062\u20138.","journal-title":"J Biol Chem"},{"key":"8845_CR7","first-page":"397","volume":"62","author":"RH Silverman","year":"2002","unstructured":"Silverman RH, Halloum A, Zhou A, Dong B, Al-Zoghaibi F, Kushner D, et al. Suppression of ovarian carcinoma cell growth in vivo by the interferon-inducible plasma membrane protein, phospholipid scramblase 1. Cancer Res. 2002;62:397\u2013402.","journal-title":"Cancer Res"},{"key":"8845_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/cas.15197","volume":"113","author":"WC Liao","year":"2022","unstructured":"Liao WC, Lin TJ, Liu YC, Wei YS, Chen GY, Feng HP, et al. Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1-STAT1 loop in lung adenocarcinoma. Cancer Sci. 2022;113:205\u201320.","journal-title":"Cancer Sci"},{"key":"8845_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110002","volume":"756","author":"S Zhou","year":"2024","unstructured":"Zhou S, Xu J, Zhu Y. Phospholipid scramblase 1 acts through the IL-6\/JAK\/STAT3 pathway to promote the malignant progression of glioma. Arch Biochem Biophys. 2024;756:110002.","journal-title":"Arch Biochem Biophys"},{"key":"8845_CR10","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.7150\/thno.43150","volume":"10","author":"P Huang","year":"2020","unstructured":"Huang P, Liao R, Chen X, Wu X, Li X, Wang Y, et al. Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer. Theranostics. 2020;10:4644\u201358.","journal-title":"Theranostics"},{"key":"8845_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41388-022-02586-2","volume":"42","author":"E Henriet","year":"2023","unstructured":"Henriet E, Knutsdottir H, Grasset EM, Dunworth M, Haynes M, Bader JS, et al. Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs. Oncogene. 2023;42:737\u201347.","journal-title":"Oncogene"},{"key":"8845_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2019.02.003","volume":"142","author":"B Peng","year":"2019","unstructured":"Peng B, He R, Xu Q, Yang Y, Hu Q, Hou H, et al. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway. Pharm Res. 2019;142:1\u201313.","journal-title":"Pharm Res"},{"key":"8845_CR13","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1158\/1078-0432.CCR-21-0714","volume":"27","author":"SB Koh","year":"2021","unstructured":"Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, et al. RASAL2 Confers Collateral MEK\/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clin Cancer Res: J Am Assoc Cancer Res. 2021;27:4883\u201397.","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"8845_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol cell Biol. 2001;2:127\u201337.","journal-title":"Nat Rev Mol cell Biol"},{"key":"8845_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3892\/or.2015.4047","volume":"34","author":"YS Kwon","year":"2015","unstructured":"Kwon YS, Chun SY, Nam KS, Kim S. Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1. Oncol Rep. 2015;34:884\u201390.","journal-title":"Oncol Rep"},{"key":"8845_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.neo.2021.05.009","volume":"23","author":"VC Mak","year":"2021","unstructured":"Mak VC, Li X, Rao L, Zhou Y, Tsao SW, Cheung LW. p85\u03b2 alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair. Neoplasia (N Y, NY). 2021;23:718\u201330.","journal-title":"Neoplasia (N Y, NY)"},{"key":"8845_CR17","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jtho.2016.05.025","volume":"11","author":"Y Shintani","year":"2016","unstructured":"Shintani Y, Fujiwara A, Kimura T, Kawamura T, Funaki S, Minami M, et al. IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling. J Thorac Oncol: Publ Int Assoc Study Lung Cancer. 2016;11:1482\u201392.","journal-title":"J Thorac Oncol: Publ Int Assoc Study Lung Cancer"},{"key":"8845_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01975-3","volume":"23","author":"F Luo","year":"2024","unstructured":"Luo F, Zhang M, Sun B, Xu C, Yang Y, Zhang Y, et al. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1\/PLK3\/HIF1alpha signaling. Mol Cancer. 2024;23:60.","journal-title":"Mol Cancer"},{"key":"8845_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102993","volume":"69","author":"X Liu","year":"2024","unstructured":"Liu X, Li P, Huang Y, Li H, Liu X, Du Y, et al. M(6)A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer. Redox Biol. 2024;69:102993.","journal-title":"Redox Biol"},{"key":"8845_CR20","volume":"12","author":"X He","year":"2025","unstructured":"He X, Li Y, Li J, Li Y, Chen S, Yan X, et al. HDAC2-mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in triple-negative breast cancer. Adv Sci (Weinh, Baden-Wurtt, Ger). 2025;12:e2413121.","journal-title":"Adv Sci (Weinh, Baden-Wurtt, Ger)"},{"key":"8845_CR21","doi-asserted-by":"publisher","first-page":"45555","DOI":"10.1021\/acsami.5c10486","volume":"17","author":"Y Tang","year":"2025","unstructured":"Tang Y, Jia C, Ning H, Zhao Y, Chang Q, Song W, et al. Breaking tumor chemoresistance via METTL3 regulation enhanced by sequential delivery of dexamethasone. ACS Appl Mater interfaces. 2025;17:45555\u201368.","journal-title":"ACS Appl Mater interfaces"},{"key":"8845_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1427","volume":"13","author":"X Zhang","year":"2023","unstructured":"Zhang X, Shi L, Sun HD, Wang ZW, Xu F, Wei JF, et al. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner. Clin Transl Med. 2023;13:e1427.","journal-title":"Clin Transl Med"},{"key":"8845_CR23","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200751RR","volume":"36","author":"T Jiang","year":"2022","unstructured":"Jiang T, He X, Zhao Z, Zhang X, Wang T, Jia L. RNA m6A reader IGF2BP3 promotes metastasis of triple-negative breast cancer via SLIT2 repression. FASEB J: Publ Fed Am Soc Exp Biol. 2022;36:e22618.","journal-title":"FASEB J: Publ Fed Am Soc Exp Biol"},{"key":"8845_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.32615\/ps.2025.016","volume":"63","author":"R Grebenok","year":"2025","unstructured":"Grebenok R, Ugine T, Galante M, Grebenok N, Iqbal H, Olszewski N, et al. Increased brassinolide accumulation and increased growth in low-light-grown transgenic tobacco. Photosynthetica. 2025;63:140\u201350.","journal-title":"Photosynthetica"},{"key":"8845_CR25","doi-asserted-by":"publisher","first-page":"12569","DOI":"10.1074\/jbc.C112.442319","volume":"288","author":"S Samanta","year":"2013","unstructured":"Samanta S, Pursell B, Mercurio AM. IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. J Biol Chem. 2013;288:12569\u201373.","journal-title":"J Biol Chem"},{"key":"8845_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9096436","volume":"2022","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Xue M, Chen J, Wang Z, Ju F, Ni J, et al. METTL14 regulates intestine cellular senescence through m(6)A modification of lamin B receptor. Oxid Med Cell Longev. 2022;2022:9096436.","journal-title":"Oxid Med Cell Longev"},{"key":"8845_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s42003-024-06477-y","volume":"7","author":"X Zeng","year":"2024","unstructured":"Zeng X, Lu Y, Zeng T, Liu W, Huang W, Yu T, et al. RNA demethylase FTO participates in malignant progression of gastric cancer by regulating SP1-AURKB-ATM pathway. Commun Biol. 2024;7:800.","journal-title":"Commun Biol"},{"key":"8845_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101289","volume":"16","author":"Y Lu","year":"2022","unstructured":"Lu Y, Cao G, Lan H, Liao H, Hu Y, Feng H, et al. Chondrocyte-derived Exosomal miR-195 Inhibits Osteosarcoma Cell Proliferation and Anti-Apoptotic by Targeting KIF4A in vitro and in vivo. Transl Oncol. 2022;16:101289.","journal-title":"Transl Oncol"},{"key":"8845_CR29","first-page":"842","volume":"55","author":"Y Lu","year":"2023","unstructured":"Lu Y, Huang P, Li Y, Liu W, Li J, Zhao R, et al. The FBXO32\/ATR\/ATM axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression. Acta Biochimica et Biophysica Sin. 2023;55:842\u201352.","journal-title":"Acta Biochimica et Biophysica Sin"},{"key":"8845_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107534","volume":"26","author":"Y Lu","year":"2023","unstructured":"Lu Y, Huang P, Zeng X, Liu W, Zhao R, Li J, et al. Inhibition of FNDC1 suppresses gastric cancer progression by interfering with G\u03b2\u03b3-VEGFR2 complex formation. iScience. 2023;26:107534.","journal-title":"iScience"},{"key":"8845_CR31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1042\/BST20191055","volume":"48","author":"S Lev","year":"2020","unstructured":"Lev S. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis. Biochem Soc Trans. 2020;48:657\u201365.","journal-title":"Biochem Soc Trans"},{"key":"8845_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","volume":"26","author":"KM Lee","year":"2017","unstructured":"Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017;26:633\u201347.e7.","journal-title":"Cell Metab"},{"key":"8845_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12964-025-02233-9","volume":"23","author":"Q Wu","year":"2025","unstructured":"Wu Q, Siddharth S, Verma D, Parida S, Sharma D. TRIM29 upregulation contributes to chemoresistance in triple negative breast cancer via modulating S100P-\u03b2-catenin axis. Cell Commun Signal. 2025;23:244.","journal-title":"Cell Commun Signal"},{"key":"8845_CR34","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s10495-024-01947-4","volume":"29","author":"AX Han","year":"2024","unstructured":"Han AX, Long BY, Li CY, Huang DD, Xiong EQ, Li FJ, et al. Machine learning framework develops neutrophil extracellular traps model for clinical outcome and immunotherapy response in lung adenocarcinoma. Apoptosis: Int J Program Cell Death. 2024;29:1090\u2013108.","journal-title":"Apoptosis: Int J Program Cell Death"},{"key":"8845_CR35","doi-asserted-by":"crossref","unstructured":"Wang X, Yang K, Wu Q, Kim LJY, Morton AR, Gimple RC, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Sci Transl Med. 2019;11:eaau4972.","DOI":"10.1126\/scitranslmed.aau4972"},{"key":"8845_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-022-04796-8","volume":"13","author":"S Song","year":"2022","unstructured":"Song S, Yu Z, You Y, Liu C, Xie X, Lv H, et al. EGFR\/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli. Cell Death Dis. 2022;13:351.","journal-title":"Cell Death Dis"},{"key":"8845_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100788","volume":"28","author":"X Deng","year":"2022","unstructured":"Deng X, Li X, Guo X, Lu Y, Xie Y, Huang X, et al. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. Neoplasia (N Y, NY). 2022;28:100788.","journal-title":"Neoplasia (N Y, NY)"},{"key":"8845_CR38","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1091\/mbc.e12-02-0132","volume":"23","author":"MA El Azreq","year":"2012","unstructured":"El Azreq MA, Naci D, Aoudjit F. Collagen\/\u03b21 integrin signaling up-regulates the ABCC1\/MRP-1 transporter in an ERK\/MAPK-dependent manner. Mol Biol cell. 2012;23:3473\u201384.","journal-title":"Mol Biol cell"},{"key":"8845_CR39","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ptr.6584","volume":"34","author":"XZ Liao","year":"2020","unstructured":"Liao XZ, Gao Y, Sun LL, Liu JH, Chen HR, Yu L, et al. Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway. Phytother Res. 2020;34:1142\u201353.","journal-title":"Phytother Res"},{"key":"8845_CR40","volume":"11","author":"T Xia","year":"2024","unstructured":"Xia T, Dai XY, Sang MY, Zhang X, Xu F, Wu J, et al. IGF2BP2 drives cell cycle progression in triple-negative breast cancer by recruiting EIF4A1 to promote the m6A-modified CDK6 translation initiation process. Adv Sci (Weinh, Baden-Wurtt, Ger). 2024;11:e2305142.","journal-title":"Adv Sci (Weinh, Baden-Wurtt, Ger)"},{"key":"8845_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.breast.2011.12.012","volume":"21","author":"M Khasraw","year":"2012","unstructured":"Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast (Edinb, Scotl). 2012;21:142\u20139.","journal-title":"Breast (Edinb, Scotl)"},{"key":"8845_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109798","volume":"354","author":"P Liu","year":"2022","unstructured":"Liu P, Zhou W, Yang L, Zhang C. E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51. Chem-Biol Interact. 2022;354:109798.","journal-title":"Chem-Biol Interact"},{"key":"8845_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13046-024-03041-8","volume":"43","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Yu Y, Li X, Guo A. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer. J Exp Clin Cancer Res. 2024;43:115.","journal-title":"J Exp Clin Cancer Res"},{"key":"8845_CR44","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12:4564\u201380.","journal-title":"Theranostics"},{"key":"8845_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41418-021-00862-4","volume":"29","author":"C Ren","year":"2022","unstructured":"Ren C, Han X, Lu C, Yang T, Qiao P, Sun Y, et al. Ubiquitination of NF-\u03baB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance. Cell Death Differ. 2022;29:381\u201392.","journal-title":"Cell Death Differ"},{"key":"8845_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59588-3","volume":"16","author":"X Qu","year":"2025","unstructured":"Qu X, Hamidi H, Johnson RM, Sokol ES, Lin E, Eng C, et al. Ligand-activated EGFR\/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. Nat Commun. 2025;16:4332.","journal-title":"Nat Commun"},{"key":"8845_CR47","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.7150\/ijbs.79965","volume":"19","author":"Y Ning","year":"2023","unstructured":"Ning Y, Zheng H, Yang Y, Zang H, Wang W, Zhan Y, et al. YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR\/MAPK pathway and abrogating autophagy in non-small cell lung cancer. Int J Biol Sci. 2023;19:2458\u201374.","journal-title":"Int J Biol Sci"},{"key":"8845_CR48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/annonc\/mdm522","volume":"19","author":"Y Eralp","year":"2008","unstructured":"Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol: J Eur Soc Med Oncol. 2008;19:669\u201374.","journal-title":"Ann Oncol: J Eur Soc Med Oncol"},{"key":"8845_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","volume":"121","author":"L Ma","year":"2005","unstructured":"Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121:179\u201393.","journal-title":"Cell"},{"key":"8845_CR50","doi-asserted-by":"publisher","first-page":"ra29","DOI":"10.1126\/scisignal.2005125","volume":"7","author":"JJ Tao","year":"2014","unstructured":"Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014;7:ra29.","journal-title":"Sci Signal"},{"key":"8845_CR51","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1007\/s13277-015-4357-3","volume":"37","author":"P Zhao","year":"2016","unstructured":"Zhao P, Ma W, Hu Z, Zang L, Tian Z, Zhang K. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK\/ERK pathway. Tumour Biol: J Int Soc Oncodev Biol Med. 2016;37:5107\u201315.","journal-title":"Tumour Biol: J Int Soc Oncodev Biol Med"},{"key":"8845_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Yu B, Tao D, Xu X, Xu Y, Wang J, et al. The role of m6A methylation in therapy resistance in cancer. Mol cancer. 2023;22:91.","journal-title":"Mol cancer"},{"key":"8845_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-020-00510-w","volume":"53","author":"X Pan","year":"2021","unstructured":"Pan X, Hong X, Li S, Meng P, Xiao F. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021;53:91\u2013102.","journal-title":"Exp Mol Med"},{"key":"8845_CR54","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.7150\/ijbs.103522","volume":"21","author":"Q Song","year":"2025","unstructured":"Song Q, Wang W, Yu H, Zhou Z, Zhuang J, Lv J, et al. IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner. Int J Biol Sci. 2025;21:2048\u201366.","journal-title":"Int J Biol Sci"},{"key":"8845_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.624395","volume":"11","author":"X Liu","year":"2021","unstructured":"Liu X, Wang P, Teng X, Zhang Z, Song S. Comprehensive analysis of expression regulation for RNA m6A regulators with clinical significance in human cancers. Front Oncol. 2021;11:624395.","journal-title":"Front Oncol"},{"key":"8845_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1628","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhou Y, Qian Y, Wei W, Lin X, Mao S, et al. m(6)A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clin Transl Med. 2024;14:e1628.","journal-title":"Clin Transl Med"},{"key":"8845_CR57","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s42003-025-08065-0","volume":"8","author":"Y Ge","year":"2025","unstructured":"Ge Y, Kong L, Li Y, Yu Z, Zhai F, Zhan Z, et al. The role of IGF2BP3\/SPOP\/c-Myc loop in paclitaxel resistance of endometrial cancer. Commun Biol. 2025;8:624.","journal-title":"Commun Biol"},{"key":"8845_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01449-3","volume":"9","author":"K Zhu","year":"2023","unstructured":"Zhu K, Gao T, Wang Z, Zhang L, Tan K, Lv Z. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation. Cell Death Discov. 2023;9:151.","journal-title":"Cell Death Discov"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08845-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:30:53Z","timestamp":1783485053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8845"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08845-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All contributors have agreed to publish this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"624"}}